Abnormal Expression of WSB1 in Lung Adenocarcinoma: A Potential Prognostic and Immunotherapeutic Sensitivity Biomarker
DOI:
https://doi.org/10.71204/1bcv8650Keywords:
Lung Adenocarcinoma, WSB1, Pan-Cancer Analysis, ImmunohistochemistryAbstract
This study aimed to conduct a pan-cancer analysis of WD40 Repeat-Containing SOCS Box Protein 1 (WSB1) through bioinformatics, detect its expression in lung adenocarcinoma (LUAD) tissues and adjacent normal tissues by immunohistochemistry (IHC), analyze its correlation with clinical indicators, and explore its diagnostic and prognostic value. We performed WSB1 bioinformatics analysis using data from multiple public databases (including TCGA, GTEx, HPA, CPTAC, etc.). IHC was used to detect the expression difference of WSB1 in LUAD tissues and adjacent normal tissues, followed by statistical processing and clinicopathological data analysis. Kaplan-Meier plotter was used to analyze the relationship between WSB1 expression and survival, and GO and KEGG pathway enrichment analyses were conducted to explore its functions. WSB1 was differentially expressed between various cancers and normal tissues. Specifically, WSB1 mRNA levels were downregulated in LUAD, while protein levels were significantly upregulated (P < 0.05). WSB1 expression was negatively correlated with LUAD distant metastasis (P < 0.05) and promoter methylation, and positively correlated with overall survival (OS), tumor immunity, and PDCD1. The genetic variation frequency of WSB1 was >4% (3.18% in LUAD), and there was no correlation with gender, age, etc. IHC validation (80 LUAD samples and 80 adjacent normal tissues) confirmed that WSB1 expression in LUAD tissues was significantly higher than that in adjacent normal tissues. WSB1 is upregulated at the protein level in LUAD and serves as a potential prognostic marker. It correlates with tumor immunity/PDCD1 (as a marker of immunotherapy sensitivity) and promoter methylation (through epigenetic regulation), and its abnormal expression may be caused by high-frequency mutations.
References
Alamri, S., Badah, M. Z., Zorgi, S., et al. (2024). Disease prognosis and therapeutic strategies in patients with advanced non-small cell lung cancer (NSCLC): A 6-year epidemiological study between 2015–2021. Translational Cancer Research, 13(2), 762–770.
Blumenschein, G. R., Smit, E. F., Planchard, D., et al. (2015). A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC). Annals of Oncology, 26(5), 894–901.
Bray, F., Laversanne, M., Weiderpass, E., et al. (2021). The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer, 127(16), 3029–3030.
Bullock, A. N., Debreczeni, J. É., Edwards, A. M., et al. (2006). Crystal structure of the SOCS2–elongin C–elongin B complex defines a prototypical SOCS box ubiquitin ligase. Proceedings of the National Academy of Sciences, 103(20), 7637–7642.
Cao, M., Li, H., Sun, D., et al. (2020). Cancer burden of major cancers in China: A need for sustainable actions. Cancer Communications, 40(5), 205–210.
Cao, W., Qin, K., Li, F., et al. (2024). Socioeconomic inequalities in cancer incidence and mortality: An analysis of GLOBOCAN 2022. Chinese Medical Journal, 137(12), 1407–1413.
Chinese Society of Oncology, Chinese Medical Association. (2024). Clinical practice guidelines for lung cancer (2024 edition). Chinese Medical Journal, 104(34), 3175–3213.
Dentice, M., Bandyopadhyay, A., Gereben, B., et al. (2005). The hedgehog-inducible ubiquitin ligase subunit WSB-1 modulates thyroid hormone activation and PTHrP secretion in the developing growth plate. Nature Cell Biology, 7(7), 698–705.
Fehrenbacher, L., Spira, A., Ballinger, M., et al. (2016). Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. The Lancet, 387(10030), 1837–1846.
Fong, H. K., Hurley, J. B., Doolittle, R. F., et al. (1986). Repetitive segmental structure of the transducin beta subunit: Homology with the CDC4 gene and identification of related mRNAs. Proceedings of the National Academy of Sciences of the United States of America.
Haque, M., Kendal, J. K., MacIsaac, R. M., et al. (2016). WSB1: From homeostasis to hypoxia. Journal of Biomedical Science, 23(1), 61.
Li, C., Tang, Z., Zhang, W., et al. (2021). GEPIA2021: Integrating multiple deconvolution-based analysis into GEPIA. Nucleic Acids Research, 49(W1), W242–W246.
Megyesfalvi, Z., Gay, C. M., Popper, H., et al. (2023). Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA: A Cancer Journal for Clinicians, 73(6), 620–652.
Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024). Cancer statistics, 2024. CA: A Cancer Journal for Clinicians, 74(1), 12–49.
Vasiliauskas, D., Hancock, S., & Stern, C. D. (1999). SWiP-1: Novel SOCS box containing WD-protein regulated by signalling centres and by Shh during development. Mechanisms of Development, 82(1–2), 79–94.
Villamil, M. A., Liang, Q., & Zhuang, Z. (2013). The WD40-repeat protein-containing deubiquitinase complex: Catalysis, regulation, and potential for therapeutic intervention. Cell Biochemistry and Biophysics, 67(1), 111–126.
Wang, Y., Hu, X. J., Zou, X. D., et al. (2015). WDSPdb: A database for WD40-repeat proteins. Nucleic Acids Research, 43(Database issue), D339–D344.
Zhang, H., Zhang, P., Lin, X., et al. (2024). Integrative single-cell analysis of LUAD: Elucidating immune cell dynamics and prognostic modeling based on exhausted CD8+ T cells. Frontiers in Immunology, 15, 1366096.
Zheng, R. S., Chen, R., Han, B. F., et al. (2024). Analysis of the cancer burden in China in 2022. Chinese Journal of Oncology, 46(3), 221–231.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Jiarui Xue, Tianying He, Shuqing Wang, Yan Liu (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles published in this journal are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are properly credited. Authors retain copyright of their work, and readers are free to copy, share, adapt, and build upon the material for any purpose, including commercial use, as long as appropriate attribution is given.
How to Cite
